Search
Products meeting the search criteria
Adora Paedia. Drops 15ml
DescriptionAdora (Cefadroxil Monohydrate) is an acid-stable semi-synthetic oral antibiotic in the cephalosporin family of drugs. Cefadroxil acts by preventing bacteria from forming protective cell wall necessary for survival. It has superior pharmacokinetic profile over all first generation cephalosporins.IndicationsAdora (Cefadroxil Monohydrate) is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases:*Upper respiratory tract infections caused by Streptococcus pyogenes (Group A beta-hemolytic Streptococci) and Streptococcus pneumoniae.* Urinary tract infections caused by E. coli, Proteus mirabilis, and Klebsiella species.* Skin and soft tissue infections caused by Staphylococci (including penicillinase producing strains) and Streptococci.Dosage & AdministrationThe bioavailability and consequent chemotherapeutic effects of Cefadroxil are unaffected by foods. It may, therefore, be taken with meals or on an empty stomach. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.IndicationAdult (dose)Children (Dose)Upper respiratory tract Infections1 gm per day in single (q.d.) or divided doses (b.i.d.) for 10 days 12 hourly30 mg/kg/day in a single or in equally divided doses every 12 hoursUrinary Tract Infections1 or 2 gm per day in single (q.d.) or divided doses (b.i.d.)30 mg/kg/day in equally divided doses every 12 hoursFor all other UTIs2 gm per day in divided doses (b.i.d)30 mg/kg/day in equally divided doses every 12 hoursSkin & soft tissue Infections1 gm per day in single (q.d.) or divided doses (b.i.d.)30 mg/kg/day in equally divided doses every 12 hoursProphylaxis against bacterial endocarditis2 gm 1 hour prior to the procedure50 mg/kg 1 hour prior to the procedureSide EffectsGenerally cefadroxil is well tolerated. However, the most commonly reported side effects are gastrointestinal disturbances and hypersensitivity phenomena. Side effects including nausea, vomiting, diarrhoea, dyspepsia, abdominal discomfort, fever, dizziness, headache, arthralgia may also occur.PrecautionsN/AUse in Pregnancy & LactationCefadroxil (Adora) is widely used as a first-line oral antibiotic for the treatment of uncomplicated urinary tract infections in pregnant women.Drug InteractionThere is no known clinically important drug interactions with Cefadroxil.Over DoseIf amounts >250 mg/kg is ingested, gastric lavage or simulation of vomiting is appropriate.Commercial PackAdora 500 mg Capsule : Box containing 5 Alu-Alu blister strips of 4 capsules.Adora Powder for Suspension : Bottle containing powder to produce 100 ml suspension when reconstituted.Adora Powder for Suspension : Bottle containing powder to produce 60 ml suspension when reconstituted.Adora Powder for Paediatric Drops: Bottle containing powder for preparation of 15 ml suspension.OthersDirection for Reconstitution of suspensionFor 100 ml suspension and 100 ml DS suspension: Add 65 ml (13 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.For 60 ml suspension: Add 40 ml (8 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.Paediatric Drops: Add 10 ml (2 measuring spoonful) to the bottle and shake vigorously.Note: Shake both oral suspension and paediatric drops well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator and unused portion should be discarded after 14 days...
Tk.50.00/=
Aerophin Nebuliser Solution 0.5ml 10'S
DescriptionRacepinephrine is an alpha- and beta-adrenoreceptor stimulant. Racepinephrine works by widening the airways, reducing spasms of bronchial muscles of asthma patients, which makes it easier to breathe.IndicationsFor temporary relief of mild symptoms of intermittent asthma: Wheezing, tightness of chest and shortness of breath.Dosage & AdministrationAdults and children 4 years of age and over-Jet Nebulizer: Nebulisation for fifteen minutes every 3 to 4 hours. One 0.5 ml ampoule should be diluted to a volume of 3 to 5 ml with sterile 0.9% sodium chloride solution.Hand-held Bulb Nebulizer: 1 to 3 inhalations not more often than every 3 hours. The racepinephrine inhalation solution does not require dilution. Should not use more than 12 inhalations in 24 hours.Children under 4 years of age: Use according to the physician’s directionSide EffectsSide effects of Racepinephrine includes headache, loss of appetite, nausea & vomiting, nervousness, tremors, trouble sleeping, fear, agitation, anxiety, restlessness, dizziness, impaired memory, hallucinations, and psychosis.Severe allergic reactions (rash, hives, itching, and difficulty in breathing, swelling of the mouth, face, lips, or tongue), chest pain, fast heartbeat and wheezing may occur. Besides, elevations of heart rate and blood pressure or arrhythmias may occur. Cardiac patients with coronary artery disease or hypertension may worsen condition.PrecautionsRacepinephrine should be used cautiously in patients with: cardiac disease (angina, tachycardia, myocardial infarction, hypertension), hyperthyroidism, diabetes, cerebral arteriosclerosis. Excessive use may lead to tolerance and paradoxical bronchospasm. Besides, it is advised not to useRacepinephrine if symptoms are not relieved within 20 minutes or become worse. Racepinephrine solution should not be used if it is brown in color or cloudy, pinkish or if it contains a precipitateUse in Pregnancy & LactationRacemic epinephrine is a 1:1 mixture of the Dextrorotatory and Levorotatory isomers of epinephrine.Epinephrine has been assigned to pregnancy category C by the US FDA. Epinephrine is only recommended for use during pregnancy when there are no alternatives and benefit outweighs the risk. Epinephrine is excreted into human milk. Due to the potential for serious adverse effects in nursing infants, a decision should be made to discontinue nursing or discontinue the drug.Drug InteractionConcurrent use with other adrenergic agents will have additive adrenergic side effects. Use with MAO inhibitors may lead to hypertensive crisis. Beta blockers may negate therapeutic effect. Tricyclic antidepressants enhance response to epinephrine.Over DoseExcessive use may cause nervousness and rapid heartbeat, adverse effects on the heart. In case of overdose, patient should get medical help right away.StorageStore at 2o - 8o C. Keep away from light and out of the reach of children...
Tk.250.00/=
Alfavir Tablet
DescriptionTenofovir Alafenamide, a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor, is converted into tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5′-monophosphate.IndicationsTenofovir Alafenamide is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.Dosage & AdministrationThe recommended dosage of Tenofovir Alafenamide is 25 mg (one tablet) taken orally once daily with food.No dosage adjustment is required in patients with mild, moderate, or severe renal impairment. Tenofovir Alafenamide is not recommended in patients with end stage renal disease (estimated creatinine clearance below 15 mL/min).No dosage adjustment is required in patients with mild hepatic impairment (Child-Pugh A). Tenofovir Alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment.Side EffectsLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate in combination with other antiretrovirals. A majority of these cases have been in women.PrecautionsTenofovir Alafenamide alone should not be used in patients with HIV infection. Lactic acidosis and severe hepatomegaly with steatosis have been reported with the use of nucleoside analogs.Discontinuation of anti-hepatitis B therapy, including Tenofovir Alafenamide, may result in severe acute exacerbations of hepatitis B. Patients who discontinue Tenofovir Alafenamide should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.Use in Pregnancy & LactationIt is not known whether Tenofovir Alafenamide and its metabolites are present in human breast milk, affect human milk production, or have effects on the breastfed infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tenofovir Alafenamide and any potential adverse effects on the breastfed infant.Drug InteractionDrugs that induce P-gp activity are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentrations of tenofovir alafenamide, which may lead to loss of therapeutic effect. Based on drug interaction studies conducted with Tenofovir Alafenamide, no clinically significant drug interactions have been observed with: ethinyl estradiol, itraconazole, ketoconazole, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, and sofosbuvir/velpatasvir.Over DoseIf overdose occurs, monitor patient for evidence of toxicity. Treatment of overdosage with Tenofovir Alafenamide consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.StorageStore in a cool, dry place & protected from light. Keep out of reach of children...
Tk.90.00/=
Algicid Plus 200 ml Suspension
DescriptionOn ingestion the product reacts rapidly with gastric acid to form a raft of alginic acid gel having a near neutral pH and which floats on the stomach contents, quickly and effectively impeding gastrooesophageal reflux, for up to 4 hours. In severe cases the raft itself may be refluxed into the esophagus, in preference to the stomach contents, and exert a demulcent effect.IndicationsGastric reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric refluxDosage & AdministrationFor oral administration.Adults and children over 12 years: 10-20ml after meals and at bedtime.Elderly: No dosage modification is required in this age group.Children 6 to 12 years: 5-10ml after meals and at bedtime.Children under 6 years: Not recommendedPrecautionsIf symptoms do not improve after seven days, the clinical situation should be reviewed. Each 10 ml dose has a sodium content of 141 mg (6.2 mmol). This should be takeninto account when a highly restricted salt diet is recommended e.g. in some cases of congestive cardiac failure and renal impairment. Each 10 ml dose contains 160 mg (1.6 mmol) of calcium carbonate. Care needs to betaken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions.Use in Pregnancy & LactationPregnancy:Clinical studies in more than 500 pregnant women as well as a large amount of data from post marketing experience indicate no malformative nor feto/ neonatal toxicity of the active substances. Algicid Plus can be used during pregnancy, if clinically needed.Breast feeding:No effects of the active substances have been shown in breastfed newborns/infants of treated mothers.Algicid Plus can be used during breast-feeding.Drug InteractionA time-interval of 2 hours should be considered between Algicid Plus intake and the administration of other medicinal products, especially tetracyclines, digoxine,fluoroquinolone, iron salt, ketoconazole, neuroleptics, thyroid hormones, penicillamine, beta-blockers (atenolol, metoprolol, propanolol), glucocorticoid, chloroquine andbiphosphonates and estramustineOver DoseOver dosage with this formulation is a rare case. In case of overdose please consult with a registered physician.StorageDo not store above 30 o C. Keep away from light and out of the reach of children..
Tk.250.00/=
Ambolyt Syrup 200ml
DescriptionAmbroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency. Beside these, Ambroxol also exhibits anti-oxidant activity. Long-term use is possible because of the good tolerability of the preparation.Indications• Acute and chronic diseases of respiratory tracts associated with viscid mucus including acute and chronic bronchitis• Productive cough• Inflammatory diseases of Rhinopharyngeal tract (e.g. Laryngitis, Pharyngitis, Sinusitis and Rhinitis) associated with viscid mucus• Asthmatic bronchitis, Bronchial asthma with difficult departure of mucus• Bronchiectasis• Chronic pneumonia.Dosage & AdministrationAverage daily dose (preferably after meal).Ambolyt Paediatric Drops:0-6 months 0.5 ml 2 times a day6-12 months 1 ml 2 times a day1-2 years 1.25 ml 2 times a dayAmbolyt Syrup:2-5 years 2.5 ml (1/2 teaspoonful) 2-3 times a day5-10 years 5 ml (1 teaspoonful) 2-3 times a day10 years and adults 10 ml (2 teaspoonful) 3 times a day.Side EffectsGastrointestinal side-effects like epigastric pain, gastric fullness may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema may occur.PrecautionsAmbroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.Use in Pregnancy & LactationPregnancy: Teratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use during pregnancy, especially in the 1st trimester.Lactation: Safety during lactation has not been established.Drug InteractionAmbroxol has no interaction with cardioactive glycosides, corticosteroids, bronchodilators, diuretics and antibiotics (normally used in the treatment of bronchopulmonary affections). But Ambroxol should not be taken simultaneously with antitussives (e.g. Codeine) because mucus, which has been liquefied by Ambroxol, might not be expectorated...
Tk.75.00/=
Amlotab 10 Tablet
DescriptionAmlodipine is a Dihydropyridine Calcium antagonist that inhibits the transmembrane influx of Calcium ions into cardiac and vascular smooth muscle. It has greater affinity towards vascular smooth muscle than on cardiac muscle. Amlodipine is peripheral vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and thereby reduces blood pressure. Amlodipine reduces tone, decreases coronary vasoreactivity and lowers cardiac oxygen demand by reducing after load.IndicationsPatients with mild to moderate hypertension (alone or in combination with other antihypertensives).The treatment of chronic stable and vasospastic angina.Raynaud\'s disease.Dosage & AdministrationFor treatment of both hypertension and angina pectoris, the usual initial dose is 5 mg once daily. If the desired therapeutic effect cannot be achieved within 2-4 weeks, the dose may be increased to a maximum dose of 10 mg once daily. Amlodipine 10 mg once daily provides symptomatic improvement in patients with Raynaud's disease.Use in children: Use of Amlodipine in children (under 12 years of age) is not recommended.Side EffectsAmlodipine is generally well tolerated. The most commonly observed side effects are headache, peripheral oedema, palpitations, flushing, dizziness, nausea, abdominal pain.PrecautionsUse in renal failureAlthough Amlodipine is excreted primarily via kidney, mild renal impairment does not appear to have an effect on the plasma concentrations. Severe renal impairment may however require a dosage reduction. Amlodipine is not dialyzable.Use in patients with impaired hepatic functionAmlodipine half-life is prolonged in patient with impaired hepatic function. Amlodipine should therefore be administered at lower (5mg) initial dose in these patients.Use in heart failureAn increased number of pulmonary oedema has been reported.Use in Pregnancy & LactationPregnancy: Safety in pregnancy has not been established.Lactation: It is not known whether Amlodipine is excreted in breast milk. It is advised to stop breastfeeding during treatment with Amlodipine.Over DoseThere is no well documented experience with Amlodipine overdosage. In case of clinically significant hypotension due to Amlodipine over dosage, calls for active cardiovascular support including monitoring of cardiac and respiratory function, elevation of extremities and attention to circulating fluid volume and urine output. Since Amlodipine is highly protein-bound, dialysis is unlikely to be of benefit...
Tk.8.00/=
Antigall 150 Tablet
DescriptionUrsodeoxycholic Acid is a naturally-occurring bile acid used to treat different hepatobiliary disorders. It decreases the secretion of cholesterol in different ways in the bile:Ursodeoxycholic Acid reduces cholesterol absorption and suppresses liver cholesterol synthesis. But it does not inhibit bile acid synthesisIndications• Dissolution of small to medium-sized radiolucent, noncalcified gall bladder stones in functioning gall bladders• Prevention of gallstone formation in obese patients experiencing rapid weight loss• Primary biliary cirrhosisDosage & AdministrationFor adults & elderly:Dissolution of gallstone: 8 - 10 mg/kg/day given in 2 or 3 divided doses.Prevention of gallstone formation: 300 mg twice daily.Primary biliary cirrhosis: 13 - 15 mg/kg/day in 2 to 4 divided doses with food.Side EffectsThis drug may give rise to nausea, vomiting, dizziness, headache, dyspepsia, diarrhea,abdominal pain and pruritus.PrecautionsExcessive diatery intake of calories and cholesterol should be avoided. Liver function testsand bilirubin levels should be monitored every month for three months after start oftherapy, and every six months thereafterUse in Pregnancy & LactationPregnancy category B. There is no adequate and well-controlled studies in pregnant andlactating women. This drug should be used only if the benefit outweighs the risk. It is notnot known whether Ursodeoxycholic Acid is excreted in human milk. So, caution should beexercised when it is administered to a lactating motherDrug InteractionThis drug should not be administered with oral contraceptive, oestrogenic hormones andother drugs which reduce the blood cholesterol level and increase the bile cholesterollevel. Concomitant administration with bile acid binding drugs including antacids, charcoaland cholestyramine should be avoided. Since this may reduce the effectiveness of thetherapy with Ursodeoxycholic Acid.Over DoseIt is unlikely that overdose will cause serious side effects. Diarrhoea may occur and it isrecommended that liver function test to be monitored..
Tk.3.00/=
Antigall 300 Tablet
DescriptionUrsodeoxycholic Acid is a naturally-occurring bile acid used to treat different hepatobiliary disorders. It decreases the secretion of cholesterol in different ways in the bile:Ursodeoxycholic Acid reduces cholesterol absorption and suppresses liver cholesterol synthesis. But it does not inhibit bile acid synthesisIndications• Dissolution of small to medium-sized radiolucent, noncalcified gall bladder stones in functioning gall bladders• Prevention of gallstone formation in obese patients experiencing rapid weight loss• Primary biliary cirrhosisDosage & AdministrationFor adults & elderly:Dissolution of gallstone: 8 - 10 mg/kg/day given in 2 or 3 divided doses.Prevention of gallstone formation: 300 mg twice daily.Primary biliary cirrhosis: 13 - 15 mg/kg/day in 2 to 4 divided doses with food.Side EffectsThis drug may give rise to nausea, vomiting, dizziness, headache, dyspepsia, diarrhea,abdominal pain and pruritus.PrecautionsExcessive diatery intake of calories and cholesterol should be avoided. Liver function testsand bilirubin levels should be monitored every month for three months after start oftherapy, and every six months thereafterUse in Pregnancy & LactationPregnancy category B. There is no adequate and well-controlled studies in pregnant andlactating women. This drug should be used only if the benefit outweighs the risk. It is notnot known whether Ursodeoxycholic Acid is excreted in human milk. So, caution should beexercised when it is administered to a lactating motherDrug InteractionThis drug should not be administered with oral contraceptive, oestrogenic hormones andother drugs which reduce the blood cholesterol level and increase the bile cholesterollevel. Concomitant administration with bile acid binding drugs including antacids, charcoaland cholestyramine should be avoided. Since this may reduce the effectiveness of thetherapy with Ursodeoxycholic Acid.Over DoseIt is unlikely that overdose will cause serious side effects. Diarrhoea may occur and it isrecommended that liver function test to be monitored..
Tk.22.00/=
Aprima 30 Tablet
DescriptionApremilast is an inhibitor of phosphodiesterase 4 (PDE4) enzyme specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism by which Apremilast exerts its therapeutic action in psoriatic arthritis patients and psoriasis patients is not well defined.IndicationsApremilast is indicated for the treatment of adult patients with active psoriatic arthritis and moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.Dosage & AdministrationThe recommended initial dosage titration of Apremilast from Day 1 to Day 5 is shown below. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy. Apremilast can be administered without regard to meals.Day 1: 10 mg in morningDay 2: 10 mg in morning and 10 mg in eveningDay 3: 10 mg in morning and 20 mg in eveningDay 4: 20 mg in morning and 20 mg in eveningDay 5: 20 mg in morning and 30 mg in eveningDay 6 and thereafter: 30 mg twice dailyDosage adjustment in patients with severe renal impairmentApremilast dosage should be reduced to 30 mg once daily in patients with severe renal impairment. For initial dosage titration, it is recommended that Apremilast be titrated using only the morning schedule and the evening doses be skipped.Side EffectsThe most frequently occurring side effects of Apremilast are nausea, diarrhea, and headache.Other less frequent side effects are upper respiratory tract infection, vomiting, nasopharyngitis, abdominal pain, hypersensitivity, gastroesophageal reflux disease, dyspepsia, fatigue, decrease appetite, cough, rash, insomnia.PrecautionsTreatment with Apremilast is associated with an increase in adverse reactions of depression. Patients, their caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider. Prescribers should carefully evaluate the risks and benefits of continuing treatment with Apremilast if such events occur.During the controlled period of the studies in psoriatic arthritis, weight decrease between 5%-10% of body weight was reported in 10% of subjects treated with Apremilast 30 mg twice daily compared to 3.3% treated with placebo.Use in Pregnancy & LactationPregnancy: Pregnancy Category C.Nursing mothers: It is not known whether Apremilast or its metabolites are present in human milk; however Apremilast was detected in milk of lactating mice. Caution should be exercised when Apremilast is administered to a nursing woman.Usage in Pediatric PatientsThe safety and effectiveness of Apremilast in pediatric patients less than18 years of age have not been established.Drug InteractionCo-administration of strong cytochrome P450 enzyme inducer, rifampin, resulted in a reduction of systemic exposure of Apremilast. Therefore, the use of cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) with Apremilast is not recommended...
Tk.60.00/=
Aritone IV Infusion
DescriptionAritone IV is a lyophilized, sterile, yellow colored porous cake or powder of water-soluble vitamins for intravenous infusion. It contains balanced amount of all the important water soluble vitamins. It is a sterile lyophilized mixture of Vitamin B1, Vitamin B2, Nicotinamide, Vitamin B6, Pantothenic Acid, Ascorbic Acid, Biotin, Folic Acid and Vitamin B12.IndicationsAritone IV is indicated as a supplement for intravenous nutrition in order to meet the daily requirements of the water-soluble vitamins in infants, adults and children.Dosage & AdministrationAdults and children age 11 years and above: One vial (10 ml) daily.Children below 11 years of age: Children weighing less than 10 kg should be given 1 ml of the dissolved mixture per kg body weight /day.Children weighing 10 kg or more should be given 10 ml (one vial) of the dissolved mixture /day.Instruction for useThe content of each vial of Aritone IV should be dissolved first and then diluted for infusion only. The content of each vial are dissolved by the aseptic addition of-1. Water for injections2. Glucose solution for infusion (5%-50%) or3. Fat emulsion (10%)Aritone IV may be added to parenteral nutrition admixtures containing carbohydrates, lipids, amino acids and electrolytes provided that compatibility and stability have been confirmed.Side EffectsAllergic reactions may occur in patients hypersensitive to any component in the preparation, for example, methyl parahydroxybenzoate or thiamine. There have been rare reports of anaphylactoid reactions following repeated injection of preparations containing thiamine. Flushing, itching or burning of the skin may occur in patients susceptible to the effects of nicotinamide. Adverse reactions that may be expected based on experience with other water-soluble vitamin compounds administered intravenously include: allergic reactions, including anaphylaxis; dermatological reactions including flushing, erythema and pruritus and CNS reactions including headache, dizziness and agitation etc.PrecautionsAritone IV must not be given undiluted. When Aritone IV is diluted with water based solutions, the admixture should be protected from light.Use in Pregnancy & LactationAnimal reproduction studies or clinical investigations during pregnancy have not been carried out with this preparation. However, there are published reports on safe administration of water soluble vitamins in this patient group.Drug InteractionFolic acid may lower the serum concentration of phenytoin. Vitamin B6 can reduce the effect of levodopa.Over DoseNo adverse effects of an overdose of water soluble vitamins have been reported, with exception of cases of extremly high parenteral doses. The possibility of hypervitaminosis A and D should be considered if the content of the Aritone IV vial is dissolved in another multivitamin injection.StorageBefore reconstitution: Store below 25 °C, protected from light. After reconstitution: The reconstituted Aritone IV should be added to the infusion solution aseptically immediately before the start of the infusion and used within 24 hours...
Tk.270.00/=
Aroneb Nebuliser Solution
DescriptionArformoterol tartrate is a salt of Arformoterol, the (R,R)-enantiomer of formoterol. Arformoterol is a selective beta 2-adrenergic bronchodilator. It has two-fold greater potency than racemic formoterol which contains both the (S,S) and (R,R)-enantiomers. The (S,S)-enantiomer is about 1,000-fold less potent as a beta2-agonist than the (R,R)-enantiomer. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung.IndicationsArformoterol is indicated for long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.Important limitations of use: Arformoterol nebuliser solution is not indicated to treat acute deteriorations of COPD. People with asthma, who take long-acting beta2-adrenergic agonist (LABA) medicines, such as Arformoterol, have an increased risk of death from asthma problemsDosage & AdministrationThe recommended dose of Arformoterol nebuliser solution is one 15 mcg unit-dose ampoule administered twice daily (morning and evening) by nebulization. A total daily dose of greater than 30 mcg (15 mcg twice daily) is not recommended.Pediatric Use: COPD does not occur in children. The safety and efficacy of Arformoterol nebuliser solution in pediatric patients have not been establishedSide EffectsMost common adverse reactions are pain, chest pain, back pain, diarrhea, sinusitis, leg cramps, dyspnea, rash, flu syndrome, peripheral edema and lung disorder. Arformoterol can cause serious side effects, including: People with asthma, who take LABA medicines, have an increased risk of death from asthma problems. Patient should get emergency medical care if:• Breathing problems worsen quickly• After the use of rescue inhaler medicine, it does not relieve breathing problemsPrecautionsArformoterol nebuliser should not be initiated in acutely deteriorating patients. It should be used with caution in patients with cardiovascular or convulsive disorders, thyrotoxicosis, or with sensitivity to sympathomimetic drugs. Life-threatening paradoxical bronchospasm can occur.Use in Pregnancy & LactationPregnancy Category C. Arformoterol nebuliser solution should be used during pregnancy, only if the potential benefit justifies the potential risk to the fetus. It is not known whether arformoterol is excreted in human milk.Drug InteractionOther adrenergic drugs may potentiate effect. Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. Beta-blockers may decrease effectiveness.Over DoseAs with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Arformoterol nebuliser solution.StorageArformoterol nebuliser solution should be stored at 2-8°c, protected from light and excessive heat. Do not freeze. Keep out of the reach of children..
Tk.40.00/=
Baritor 2 mg Tab
Indication:Baricitinib is indicated for the treatment of adult patients with moderately to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.Dosage & Administration:The recommended dose of Baricitinib is 2 mg once daily. It may be used as monotherapy or in combination with methotrexate or other DMARDs. Baricitinib can be given orally with or without food.Preparation:Each box contains 10/20/30/40/50 tablets in blister pack...
Tk.25.00/=
Bemsivir 5mg ml IV Infusion
Remdesivir has an FDA Emergency Use Authorization for use in adults and children with suspected or confirmed COVID-19 in hospital with an oxygen saturation ≤ 94%* চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুনTherapeutic ClassAnti-viral drugsDescriptionRemdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola. In 2017, its activity against the coronavirus family of viruses was also demonstrated. Remdesivir is also being researched as a potential treatment to SARS-CoV-2, the coronavirus responsible for COVID-19. Remdesivir was granted an FDA Emergency Use Authorization on 1 May 2020. This is not the same as an FDA approval.PharmacologyRemdesivir is a nucleoside analog that is expected to inhibit the action of RNA polymerase. By incorporating into RNA, additional nucleotides cannot be added, terminating RNA transcription. Viruses with mutations in RNA polymerase to develop partial resistance to remdesivir have been shown to be less infective.Dosage & AdministrationThe FDA Emergency Use Authorization suggests a loading dose of 200 mg once daily in patients ≥ 40 kg or 5 mg/kg once daily in patients 3.5 kg to less than 40 kg, followed by a maintenance dose of 100 mg once daily in patients ≥ 40 kg or 2.5 mg/kg once daily in patients 3.5 kg to less than 40 kg. Patients not needing invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) should be treated for 5 days (including the loading dose on day 1), up to 10 days if they do not show improvement. Patients requiring invasive mechanical ventilation or ECMO should be treated for 10 days.Clinical trials used a regimen of 200mg once daily on the first day, followed by 100mg once daily for another 9 days. Early data suggests that some patients may benefit from only 5 days of treatment.Remdesivir was originally investigated as a treatment for Ebola virus, but has potential to treat a variety of RNA viruses. Its activity against the coronavirus (CoV) family of viruses, such as SARS-CoV and MERS-CoV, was described in 2017, and it is also being investigated as a potential treatment for SARS-CoV-2 infections.* চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুনContraindicationsRemdesivir is contraindicated in patients with known hypersensitivity to any ingredient of remdesivir.Side EffectsAn adverse reaction associated with remdesivir in clinical trials in healthy adult subjects was increased liver transaminases. Additional adverse reactions associated with the drug, some of which may be serious, may become apparent with more widespread use.Pregnancy & LactationRemdesivir should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.PrecautionsThere are limited clinical data available for remdesivir. Serious and unexpected adverse events may occur that have not been previously reported with remdesivir use.Use in Special PopulationThe pharmacokinetics of remdesivir have not been evaluated in patients with renal impairment. The pharmacokinetics of remdesivir have not been evaluated in patients with hepatic impairment. It is not known if dosage adjustment is needed in patients with hepatic impairment and remdesivir should only be used in patients with hepatic impairment if the potential benefit outweighs the potential risk.Storage ConditionsStore diluted remdesivir solution for infusion up to 4 hours at room temperature (20°C to 25°C) or 24 hours at refrigerated temperature (2°C to 8°C).Prior to dilution, equilibrate remdesivir injection to room temperature (20°C to 25°C). Sealed vials can be stored up to 12 hours at room temperature prior to dilution...
Tk.5,500.00/=
Brezofil 400 SR Tablet
Brezofil 400 SR TabletDescriptionDoxofylline, a new generation xanthine belonging to a new class of drug referred to as Novofylline, which is chemically 1,3-dimethyl-3,7-dihydro-purine-2,6-dione. Its molecular formula is C11H14N4O4 and its molecular weight is 266.253 g/mol. Doxofylline is a new creation long lasting oral methylxanthine extract. Methylxanthines are from the family of phosphodiesterase inhibitors. Correspondingly, its system of activity is associated to the reticence of phosphodiesterase action, initiating in bronchodilating actions. It has a bronchodilator effect which reduces rate of breathlessness in patients suffering from asthma. It helps relax the muscles in the bronchi and bronchioles, thus causing dilatation of the air passages and helping patients to breathe easily. The drug also possesses antitussive properties which help to control the cough linked with lung disorders.IndicationsDoxofylline is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxofylline is not designed for use as an emergency treatment during an asthma attack.Dosage & AdministrationTabletAdults: 400 mg sustained release tablet once a day. Single dose, administration in the evening reduces nocturnal, symptoms and helps to keep the patients complaint free during the day. However, in certain cases, 400 mg tablet twice daily is recommended on the basis of the clinical response and according to disease severity. Doses as high as 1200mg/day (400 mg 3 times day) may also be prescribed.Elderly: The dosage may be decreased according to medical prescription in the very elderly patients with concomitant cardiovascular, hepatic, renal and gastric disease, to 200 mg tablet b.i.d/ t.i.d.Children >12 years: 200 mg 2 or 3 times daily.SyrupChildren> 12 years: 10 ml, 2 or 3 times daily.Children<12 years: 6 mg/kg/dose twice daily. In case of unsatisfactory response it can be increased up to 9 mg/kg/dose twice daily under medical supervision.DosageWeightof the child10 kg15 kg20 kg25 kg30 kg35 kg40 kg6 mg/kg/dose b.i.d3 ml4.5 ml6 ml7.5 ml9 ml10.5 ml12 mlTotal daily dose6 ml9 ml12 ml15 ml18 ml21 ml24 mlElderly: 10 ml, 2 or 3 times dailySide EffectsAfter xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician.PrecautionsUse with caution in patients with hypoxemia, hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer and in elderly. Frequently, patients with Congestive Heart Failure (CHF) have markedly prolonged drug serum levels following discontinuation of Doxofylline.Use in Pregnancy & LactationAnimal reproduction studies indicate that Doxofylline does not cause fetal harm when administered to pregnant animals nor can affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to a pregnant woman only if clearly needed.Drug InteractionDoxofylline should not be administered together with other xanthine derivatives. Toxic synergism with ephedrine has been documented for xanthines. Like other xanthines, concomitant therapy with erythromycin. troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol and anti-flu vaccine may decrease the hepatic clearance of xanthines causing an increase in blood levels. No evidence of a relationship between Doxofylline serum concentrations and toxic events have been reported.Over DoseAlthough no major arrhythmias have been documented with Doxofylline, the occurrence of major cardiac rhythm disturbances cannot be excluded in case of overdosage of xanthine compounds. If a potential oral overdose is established, the patient may present with seizures; this symptom could be the first sign of intoxication. Adverse reactions may cause withdrawal from treatment...
Tk.10.00/=
Brezofil 60 ml Syrup
Brezofil 60 ml SyrupDescriptionDoxofylline, a new generation xanthine belonging to a new class of drug referred to as Novofylline, which is chemically 1,3-dimethyl-3,7-dihydro-purine-2,6-dione. Its molecular formula is C11H14N4O4 and its molecular weight is 266.253 g/mol. Doxofylline is a new creation long lasting oral methylxanthine extract. Methylxanthines are from the family of phosphodiesterase inhibitors. Correspondingly, its system of activity is associated to the reticence of phosphodiesterase action, initiating in bronchodilating actions. It has a bronchodilator effect which reduces rate of breathlessness in patients suffering from asthma. It helps relax the muscles in the bronchi and bronchioles, thus causing dilatation of the air passages and helping patients to breathe easily. The drug also possesses antitussive properties which help to control the cough linked with lung disorders.IndicationsDoxofylline is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxofylline is not designed for use as an emergency treatment during an asthma attack.Dosage & AdministrationTabletAdults: 400 mg sustained release tablet once a day. Single dose, administration in the evening reduces nocturnal, symptoms and helps to keep the patients complaint free during the day. However, in certain cases, 400 mg tablet twice daily is recommended on the basis of the clinical response and according to disease severity. Doses as high as 1200mg/day (400 mg 3 times day) may also be prescribed.Elderly: The dosage may be decreased according to medical prescription in the very elderly patients with concomitant cardiovascular, hepatic, renal and gastric disease, to 200 mg tablet b.i.d/ t.i.d.Children >12 years: 200 mg 2 or 3 times daily.SyrupChildren> 12 years: 10 ml, 2 or 3 times daily.Children<12 years: 6 mg/kg/dose twice daily. In case of unsatisfactory response it can be increased up to 9 mg/kg/dose twice daily under medical supervision.DosageWeightof the child10 kg15 kg20 kg25 kg30 kg35 kg40 kg6 mg/kg/dose b.i.d3 ml4.5 ml6 ml7.5 ml9 ml10.5 ml12 mlTotal daily dose6 ml9 ml12 ml15 ml18 ml21 ml24 mlElderly: 10 ml, 2 or 3 times dailySide EffectsAfter xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician.PrecautionsUse with caution in patients with hypoxemia, hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer and in elderly. Frequently, patients with Congestive Heart Failure (CHF) have markedly prolonged drug serum levels following discontinuation of Doxofylline.Use in Pregnancy & LactationAnimal reproduction studies indicate that Doxofylline does not cause fetal harm when administered to pregnant animals nor can affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to a pregnant woman only if clearly needed.Drug InteractionDoxofylline should not be administered together with other xanthine derivatives. Toxic synergism with ephedrine has been documented for xanthines. Like other xanthines, concomitant therapy with erythromycin. troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol and anti-flu vaccine may decrease the hepatic clearance of xanthines causing an increase in blood levels. No evidence of a relationship between Doxofylline serum concentrations and toxic events have been reported.Over DoseAlthough no major arrhythmias have been documented with Doxofylline, the occurrence of major cardiac rhythm disturbances cannot be excluded in case of overdosage of xanthine compounds. If a potential oral overdose is established, the patient may present with seizures; this symptom could be the first sign of intoxication. Adverse reactions may cause withdrawal from treatment...
Tk.60.00/=
Budicort ER Tablet
Budicort ER TabletDescriptionBudesonide is a synthetic corticosteroid having potent glucocorticoid activity and weak mineralocorticoid activity. It has approximately 200-fold higher affinity for the glucocorticoid receptor than cortisol and 15-fold than prednisolone. Budesonide is effective against inflammatory bowel diseases. It reduces inflammation of colon and also helps heal the lining of the colon..IndicationsBudesonide is a glucocorticoid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.Dosage & AdministrationOne 9 mg Budicort ER tablet should be taken once daily in the morning with or without food for up to 8 weeks or as prescribed by the doctor.Side Effects● headache● nausea● upper abdominal pain● fatigue● acne● flatulence● joint pain● urinary tract infection● abdominal distension● constipationPrecautions● Since budesonide is a glucocorticoid, general warnings concerning glucocorticoids should be followed.● Risk of impaired adrenal function when transferring from glucocorticoid treatment with higher systemiceffects to glucocorticoid treatment with lower systemic effects, such as budesonide. Taper patients slowly fromsystemic corticosteroids if transferring to budesonide.● Potential worsening of infections (e.g., chickenpox, measles, existing tuberculosis, fungal, bacterial, viral, orparasitic infection). Use with caution in patients with these infections.● Reduced liver function affects the elimination of glucocorticoid, and increases systemic availability of oralbudesonide.Use in Pregnancy & LactationPregnancy Category CThere are no adequate and well-controlled studies in pregnant women. Budesonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Nursing mothersBudesonide is secreted in human milk. So, a decision should be made whether to discontinue nursing or budesonide taking into account the clinical importance of the drug to the mother.Use in childrenSafety and effectiveness of budesonide in pediatric patients have not been established.Use in Hepatic Impaired patientsMonitor patients for signs and/or symptoms of hypercorticism.Drug InteractionAvoid Cytochrome P450 3A4 inhibitors (e.g. ketoconazole, grapefruit juice). It may cause increased systemic corticosteroid effects. Budesonide does not affect the plasma levels of oral contraceptives.Over DoseIf glucocorticoids are used at excessive doses for prolonged periods, systemic glucocorticoid effects such as hypercorticism and adrenal suppression may occur.StorageBudesonide extended-release tablets should be stored below 30°C. Store in a cool and dry place protected from light and moisture.Commercial PackBudicort ER: Each box contains 3 blister strips of 10 tablets...
Tk.30.00/=
Cabolac Tablet
DescriptionCabolac Tablet contains Cabergoline, a dopamine receptor agonist. Cabergoline is a dopaminergic ergoline derivative with potent and long-lasting prolactin lowering activity. It acts by direct stimulation of the D2-dopamine receptors on pituitary lactotrophs, thus inhibiting prolactin secretion.Indications1. Cabolac is indicated for the inhibition of physiological lactation soon after delivery, stillbirth, abortion or miscarriage.2. Cabolac is indicated for the treatment of dysfunctions associated with hyperprolactinaemia, including- amenorrhoea, oligomenorrhoea, anovulation and galactorrhoea. Cabolac is indicated in patients with prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), idiopathic hyperprolactinaemia, or empty sella syndrome with associated hyperprolactinaemia, which represent the basic underlying pathologies contributing to the above clinical manifestations.Dosage & AdministrationCabolac is to be administered by the oral route. It should be preferably taken with meals.The recommended dosage of Cabolac tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient's serum prolactin level. Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. After a normal serum prolactin level has been maintained for 6 months, Cabolac may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabolac should be reinstituted.Inhibition of physiological lactation: Cabolac should be administered during the first day after delivery. The recommended therapeutic dose is 1mg (two 0.5mg tablets) as a single dose.To stop lactation once have started to breastfeed: 0.25 mg (one half of Cabolac 0.5 mg tablet) every 12 hours for two days.Treatment of hyperprolactinaemic disorders: The recommended initial dosage of Cabolac is 0.5mg per week given in one or two (½ of a 0.5mg tablet) doses (e.g. on Monday and Thursday) per week. The weekly dose should be increased gradually preferably by adding 0.5mg per week at monthly intervals. The therapeutic dosage is usually 1mg per week and ranges from 0.25 to 2mg per week. Doses of Cabolac up to 4.5mg per week have been used in hyperprolactinaemic patients until the optimal therapeutic response is achieved.Severe hepatic insufficiency: Lower doses should be considered in patients with severe hepatic insufficiency.Children: The safety and efficacy of Cabergoline has not been established in subjects less than 16 years of age.Elderly: Data for use of Cabergoline in elderly is very limited. Available data do not indicate a special risk.Side EffectsAll side effects were mild to moderate in severity and of a transient nature. The most frequently occurring adverse events were dizziness/vertigo, headache, nausea and abdominal pain. In addition rarely palpitations, epigastric pain, somnolence, epistaxis and transient hemianopsia, vomiting, syncope, asthenia, and hot flushes were reported. Cabolac withdrawal results in reversal of side effects, usually within a few days after discontinuation.Asymptomatic decreases in blood pressure (20mmHg systolic and 10mmHg diastolic) may occur usually once during the first 3-4 days after child birth.PrecautionsHypersensitive (allergic) to Cabergoline, to other medicines called ergot alkaloids, (e.g. pergolide, bromocriptine, lisuride, ergotamine or ergometrine) or to any of the other ingredients in the tablet.Severe liver disease and High blood pressure in pregnancy associated with swelling and protein in the urine.Anti-psychotics or have a history of mental illness associated with child-birth.Use in Pregnancy & LactationTreated with Cabergoline for a long period and have or had fibrotic reactions (scar tissue) affecting your heart.During pregnancy: Before Cabolac administration, pregnancy should be excluded. Cabolac should be used during pregnancy only if clearly needed. If conception occurs during therapy with Cabolac, discontinuation of treatment should be considered, after careful evaluation of the risks and benefits to mother and foetus.During lactation: No information is available on the excretion in breast milk in humans; however, mothers should be advised not to breast-feed in case of failed lactation inhibition/suppression by Cabolac. Since it prevents lactation, Cabolac should not be administered to mothers with hyperprolactinaemic disorders who wish to breast-feed their infants.Drug InteractionCabolac should not be administered concurrently with –D2 antagonists, such as Phenothiazines, Butyrophenones, Thioxanthenes, Or Metoclopramide.Medicines to lower blood..
Tk.80.00/=
Calvimax-D Tablet 30's pack
Calvimax-D Tablet 30's pack: ৳ 150DescriptionCalcium is an essential element and plays vital roles in the body. It helps body's framework stronger by building bone. Clinical evidence suggests that calcium is useful for prevention and treatment of osteoporosis and associated fractures. Vitamin-D is also essential for healthy bones as it aids in calcium absorption from the GI tract. In addition to this it stimulates bone formation. Controlled clinical studies shows that calcium and vitamin-D has synergistic effects on bone growth as well as in osteoporosis and fracture prevention.Indications• Treatment of osteoporosis, rickets, osteomalacia, tetany and hypoparathyroidism• In pregnancy & lactation due to increase demand• In kidney disease and pancreatitis• During therapy with antiseizure medications• The prevention and treatment of calcium deficiency/vitamin D deficiency especially in the housebound and institutionalized elderly subjects.Dosage & AdministrationAdults and Elderly and children above 12 years of age: 2 tablets per day, preferably one tablet each morning and evening.Children: Not recommended for children under 12 years.Side EffectsThe use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain, diarrhoea. Following administration of vitamin D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases hypercalcaemia have been seen with long term treatment at high dosages.PrecautionsPatients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully. Periodic checks of plasma calcium levels and urinary calcium excretion should be made in patients with mild to moderate renal failure or mild hypercalciuria. Urinary calcium excretion should also be measured. In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria. With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours. Allowances should be made for calcium and vitamin D supplements from other sources.Use in Pregnancy & LactationDuring pregnancy and lactation treatment should always be under the direction of a physician. During pregnancy and lactation, requirements for calcium and vitamin D are increased but in deciding on the required supplementation allowances should be made for availability of these agents from other sources. If calcium iron supplements are both required to be administered to the patient, they should be taken at different times. Overdoses of vitamin D have shown teratogenic effects in pregnant animals. In humans, long term hypercalcaemia can lead to physical and mental retardation, aortic stenosis and retinopathy in a new born child. Vitamin D and its metabolites pass into the breast milk.Over DoseThe most serious consequence of acute or chronic overdose is hypercalcaemia due to vitamin D toxicity. Symptoms include nausea, vomiting, polyuria, and constipation. Chronic overdoses can lead to vascular and organ calcification as a result of hypercalcaemia. Treatment should consist of stopping all intake of calcium and vitamin D and rehydration...
Tk.150.00/=
Candirox 15 gm Cream
DescriptionCiclopirox Olamine is a synthetic, broad-spectrum, antifungal agent. The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt.IndicationsCiclopirox cream is indicated for the topical treatment of the following dermal infections:Tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum and Microsporum canis Candidiasis moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfurDosage & AdministrationGently massage Ciclopirox cream into the affected and surrounding skin areas twice daily, in the morning and evening for four weeks. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.Side EffectsCiclopirox Olamine cream is well tolerated with a low incidence of side effects. The most frequently reported events are itching, redness, burning, dryness, or irritation of treated skin.PrecautionsIf a reaction suggesting sensitivity or chemical irritation occurs with the use of Ciclopirox Cream, treatment should be discontinued and appropriate therapy instituted.Use in Pregnancy & LactationPregnancy Category B. There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox cream is administered to nursing women.Drug InteractionSafety and effectiveness in children below the age of 10 years have not been established.StorageStore in a cool and dry place protected from light. Keep out of the reach of children.Commercial PackCandirox Cream: Each tube contains 15 gm cream...
Tk.110.00/=
Carbestop Injection 1ml
DescriptionCarboprost is a synthetic prostaglandin analogue of PGF2α that acts to increase the contractions of the uterus (womb) and can trigger abortion in early pregnancy. This also helps to control excessive bleeding after delivery.IndicationsTerminating pregnancy between the 13th and 20th weeks of gestationIn the following conditions related to second trimester abortion:1. Failure of expulsion of the fetus during the course of treatment by another method;2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity;3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus;4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.Treatment of postpartum hemorrhage due to the uterus failing to return to its normal size and who have not responded to conventional treatments.Dosage & Administration1. Abortion and Indications 1–4An initial dose of 1 ml of Carbestop (containing the equivalent of 250 mcg of Carboprost) is to be administered intramuscularly. Subsequent doses of 250 mcg should be administered at 1½ to 3½ hour intervals depending on uterine response. An optional test dose of 100 mcg (0.4 ml) may be administered initially. The dose may be increased to 500 micrograms (2 ml) if uterine contractility is judged to be inadequate after several doses of 250 mcg (1 ml). The total dose administered of Carbestop should not exceed 12 mg and continuous administration of the drug for more than 2 days is not recommended.2. For Refractory Postpartum Uterine Bleeding:An initial dose of 250 mcg of Carbestop (1 ml) is to be given deep, intramuscularly (IM). If needed the dose of 1 ml may be repeated between 15 to 90 minutes. The total dose of Carbestop should not exceed 2 mg (8 doses).Side EffectsThe most frequent adverse reactions observed are related to its contractile effect on smooth muscle, especially gastrointestinal effects like vomiting, nausea, diarrhea and pyrexia.Endometritis, retained placental fragments, and excessive uterine bleeding occurred as the most common complications after abortion with Carboprost.Precautions• Use Carboprost by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.• Use Carboprost cautiously in patients with a history of asthma, hypo- or hypertension, cardiovascular, renal or hepatic disease, anemia, jaundice, diabetes or epilepsy and compromised (scarred) uteri.• In few patients with chorioamnionitis, uterus may not respond to Carboprost.• Cervix should always be carefully examined immediately post-abortion.Use in Pregnancy & LactationPregnancy category CDrug InteractionCarboprost may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.StorageStore at 2-8°C. Do not freeze. Keep away from light. Once the ampoule has been opened, the product should be used immediately...
Tk.200.00/=
Carilax 250 Tablet
DescriptionCarisoprodol is a GABA-A receptor indirect agonist with CNS chloride channel conductance effect. GABA receptor agonists typically produce sedative effect and may also cause other effects such as anxiolytic, anticonvulsant and muscle relaxant. Metabolite of Carisoprodol, Meprobamate, has anxiolytic and sedative properties.Carisoprodol decreases the impulses from brain and spinal cord to the muscle. This causes the muscle to relax and hence decrease the spasm. It has no direct action on muscle itself.IndicationsCarilax is indicated for-The relief of discomfort associated with acute, painful usculoskeletal conditions in adults. Sedation and decrease anxiety in patients with severe pain.Used as an adjunct in physical therapy in injuries.Dosage & AdministrationAdults (18 years and older): The recommended dose of Carilax is 250 mg three times daily and at bedtime (4 times daily). The recommended maximum duration of Carilax use is up to two or three weeks. Caution should be taken in patients with renal and hepatic impairment and also with reduced CYP2C19 activity.Side EffectsCommon side effects are drowsiness, dizziness and headache.PrecautionsUse in Pregnancy & LactationPregnancy category: C.Maternal use of Carisoprodol may lead to reduced or less effective infant feeding (due to sedation) and/or decresed milk production. Caution should be exercised when Carisoprodol is administered to a nursing woman.Drug InteractionCaution should be exercised with patients who take other CNS depressants (eg.- alcohol, benzodiazepines, opioids, tricyclic antidepressants) with Carisoprodol.Co-administration of CYP2C19 inhibitors (Omeprazole, Fluvoxamine) with Carisoprodol could result in increased exposure of Carisoprodol. Co-administration of CYP2C19 inducers (Rifampin) with Carisoprodol could result in decreased exposure of arisoprodol.Over DoseOverdosage of Carisoprodol commonly produces CNS depression. Death, coma, respiratory depression, hypotension, seizures have been reported with Carisoprodol overdosage.Basic life support measures should be instituted in Carisoprodol overdose. Induced emesis is not recommended due to the risk of CNS and respiratory depression. Gastric lavage should be considered soon after ingestion (within one hour). Circulatory support should be administered with volume infusion and vasopressor agents if needed. Seizures should be treated with intravenous benzodiazepines and the reoccurrence of seizures may be treated with phenobarbital. In cases of severe CNS depression, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support.StorageStore in cool and dry place at room temperature 20° - 25°C, away from direct light. Keep out reach of children...
Tk.6.00/=
Caterol 150 Convicap
DescriptionIndacaterol Maleate is a selective β2-adrenergic agonist. Its chemical name is (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl]-8hydroxy-1H-quinolin-2-one maleate. Indacaterol Maleate has a molecular weight of 508.56, and its empirical formula is C24H28N2O3 • C4H4O4. Indacaterol Maleate is white to very slightly grayish or very slightly yellowish powder. Indacaterol Maleate is freely soluble in Nmethylpyrrolidone and dimethylformamide, slightly soluble in methanol, ethanol, propylene glycol and polyethylene glycol 400, very slightly soluble in water, isopropyl alcohol and practically insoluble in 0.9% sodium chloride in water, ethyl acetate, and n-octanol.IndicationsIndacaterol Maleate is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.Dosage & AdministrationThe recommended dose is 75-150 µg according to patient’s condition once a day, Themaximum dose is 300 microgram once daily with regard to breathlessness, particularly forpatients with severe COPD.Side EffectsThe common side effects experienced are Cough, Orophary Headache, Nausea. Few side effects may result like musculos disorders: muscle spasm, musculoskeletal pain, peripherahyperglycemia, sinusitis, upper respiratory tract infection.PrecautionsIndacaterol should not be initiated in patients with acutely deteriorating COPD.Use in Pregnancy & LactationPregnancy Category C.There are no adequate and well-controlled studies with Indacaterol in pregnant women.Indacaterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation:Caution should be used when Indacaterol is administered to nursing women.Drug InteractionAdrenergic drugs, xanthine derivatives, steroids, or diuretics, non-potassium sparingdiuretics, monoamine oxidase inhibitors, tricyclic antidepressants, QTc prolonging drugs,beta-blockers, inhibitors of cytochrome P450 3A4 and P-gp efflux transporter may interactwith Indacaterol.Over DoseIn COPD patients, single doses of 10 times, the maximum recommended therapeutic dose were associated with a moderate increase in pulse rate, systolic blood pressure and QTc interval. An overdose of Indacaterol is likely to lead to exaggerated effects typical of β2-adrenergic stimulants, i.e. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia and hyperglycaemia.StorageProtect from light, store in cool & dry place.Do not store above 30°C.Keep out of the reach of children.Protect from freezing. Insert the ConviCap in the ConviHaler just prior to use to protect from deterioration by moisture...
Tk.35.00/=
Caterol 75 Convicap
DescriptionIndacaterol Maleate is a selective β2-adrenergic agonist. Its chemical name is (R)-5-[2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl]-8hydroxy-1H-quinolin-2-one maleate. Indacaterol Maleate has a molecular weight of 508.56, and its empirical formula is C24H28N2O3 • C4H4O4. Indacaterol Maleate is white to very slightly grayish or very slightly yellowish powder. Indacaterol Maleate is freely soluble in Nmethylpyrrolidone and dimethylformamide, slightly soluble in methanol, ethanol, propylene glycol and polyethylene glycol 400, very slightly soluble in water, isopropyl alcohol and practically insoluble in 0.9% sodium chloride in water, ethyl acetate, and n-octanol.IndicationsIndacaterol Maleate is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.Dosage & AdministrationThe recommended dose is 75-150 µg according to patient’s condition once a day, Themaximum dose is 300 microgram once daily with regard to breathlessness, particularly forpatients with severe COPD.Side EffectsThe common side effects experienced are Cough, Orophary Headache, Nausea. Few side effects may result like musculos disorders: muscle spasm, musculoskeletal pain, peripherahyperglycemia, sinusitis, upper respiratory tract infection.PrecautionsIndacaterol should not be initiated in patients with acutely deteriorating COPD.Use in Pregnancy & LactationPregnancy Category C.There are no adequate and well-controlled studies with Indacaterol in pregnant women.Indacaterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Lactation:Caution should be used when Indacaterol is administered to nursing women.Drug InteractionAdrenergic drugs, xanthine derivatives, steroids, or diuretics, non-potassium sparingdiuretics, monoamine oxidase inhibitors, tricyclic antidepressants, QTc prolonging drugs,beta-blockers, inhibitors of cytochrome P450 3A4 and P-gp efflux transporter may interactwith Indacaterol.Over DoseIn COPD patients, single doses of 10 times, the maximum recommended therapeutic dose were associated with a moderate increase in pulse rate, systolic blood pressure and QTc interval. An overdose of Indacaterol is likely to lead to exaggerated effects typical of β2-adrenergic stimulants, i.e. tachycardia, tremor, palpitations, headache, nausea, vomiting, drowsiness, ventricular arrhythmias, metabolic acidosis, hypokalaemia and hyperglycaemia.StorageProtect from light, store in cool & dry place.Do not store above 30°C.Keep out of the reach of children.Protect from freezing. Insert the ConviCap in the ConviHaler just prior to use to protect from deterioration by moisture...
Tk.18.00/=
Cefazol 1gm IV Injection
DescriptionCefazolin is a 1st generation semi-synthetic cephalosporin antibiotic for parenteral administration. It comes in a white to yellowish powder for injection formIndicationsCefazolin is indicated in the treatment of the following serious infections-Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella, H. influenzae, S. aureus and group A beta-hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx.Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci .Skin and Skin Structure Infections: Due to S. aureus, group A beta-hemolytic streptococci, and other strains of streptococci .Biliary Tract Infections: Due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species and S. aureus .Bone and Joint Infections: Due to S. aureus.Genital Infections: Due to E . coli, P . mirabilis, Klebsiella species, and some strains of enterococci .Septicemia: Due to S. pneumoniae, S. aureus, P. mirabilis, E. coli, and Klebsiella species .Endocarditis: Due to S. aureus and group A beta-hemolytic streptococci . Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients.Dosage & AdministrationUsual Adult Dosage• For moderate to severe infection dose is 500 mg to 1 gm and frequency is every 6 to 8 hours• For mild infections caused by Gram positive cocci dose is 250 mg to m00 mg and frequency is every 8 hours• For acute uncomplicated urinary tract infection dose is 1 gm and frequency is every 12 hours• For pneumococcal pneumonia dose is 500 gm and frequency is every 12 hours• For severe life threatening infections dose is 1 gm to 1.5 gm and frequency is every 6 hoursPerioperative Prophylactic dose: To prevent postoperative infection, the recommended doses are: I. 1 gm IV or IM administered 1/2 hour to 1 hour prior to the start of surgery II . For lengthy surgery (e.g. 2 hours or more), 500 mg to 1 gm IV or IM during surgery III. 500 mg to 1 gm IV or IM every 6 to 8 hours for 24 hours postoperativelyIntramuscular Administration: Reconstitute vials with sterile Water for Injection. Shake well until dissolved. Cefazolin should be injected into a large muscle massIntravenous Administration: For direct injection reconstitution, dilute vials with approximately 10 ml Sterile Water for Injection for 500 mg and 1 gm. Inject the solution slowly over 3 to 5 minutes. For continuous infusion dilute reconstituted in 50 to 100 mL of one of the following solutions: 0.9% Sodium Chloride Injection,5% or 10% Dextrose Injection, 5% Dextrose and 0 .9% Sodium Chloride Injection.Pediatric Dosage: In pediatric patients, a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg of body weight for severe infections. Since safety of Cefazolin use in infants has not been established, it is not recommendedSide EffectsSwelling, redness, pain, or soreness at the injection site may occur. This medication may also rarely cause loss of appetite, nausea, vomiting, diarrhea or headachePrecautionsWhen Cefazolin is administered to patients with impaired renal function, a lower daily dosage is required or otherwise, seizures may occur. it should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.Use in Pregnancy & LactationThere are no adequate studies in pregnant women for this drug so this drug should be used during pregnancy only if clearly needed. Cefazolin is present in very low concentrations in the milk of nursing mothers so caution should be exercised.Drug InteractionProbenecid may decrease renal tubular secretion of Cefazolin, when used concurrently, resulting in increased Cefazolin blood levelsStorageDo not store above 30 0C. Keep away from light and out of the reach of children..
Tk.200.00/=
Cefazol 500mg IV Injection
DescriptionCefazolin is a 1st generation semi-synthetic cephalosporin antibiotic for parenteral administration. It comes in a white to yellowish powder for injection formIndicationsCefazolin is indicated in the treatment of the following serious infections-Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella, H. influenzae, S. aureus and group A beta-hemolytic streptococci. Cefazolin is effective in the eradication of streptococci from the nasopharynx.Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci .Skin and Skin Structure Infections: Due to S. aureus, group A beta-hemolytic streptococci, and other strains of streptococci .Biliary Tract Infections: Due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species and S. aureus .Bone and Joint Infections: Due to S. aureus.Genital Infections: Due to E . coli, P . mirabilis, Klebsiella species, and some strains of enterococci .Septicemia: Due to S. pneumoniae, S. aureus, P. mirabilis, E. coli, and Klebsiella species .Endocarditis: Due to S. aureus and group A beta-hemolytic streptococci . Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients.Dosage & AdministrationUsual Adult Dosage• For moderate to severe infection dose is 500 mg to 1 gm and frequency is every 6 to 8 hours• For mild infections caused by Gram positive cocci dose is 250 mg to m00 mg and frequency is every 8 hours• For acute uncomplicated urinary tract infection dose is 1 gm and frequency is every 12 hours• For pneumococcal pneumonia dose is 500 gm and frequency is every 12 hours• For severe life threatening infections dose is 1 gm to 1.5 gm and frequency is every 6 hoursPerioperative Prophylactic dose: To prevent postoperative infection, the recommended doses are: I. 1 gm IV or IM administered 1/2 hour to 1 hour prior to the start of surgery II . For lengthy surgery (e.g. 2 hours or more), 500 mg to 1 gm IV or IM during surgery III. 500 mg to 1 gm IV or IM every 6 to 8 hours for 24 hours postoperativelyIntramuscular Administration: Reconstitute vials with sterile Water for Injection. Shake well until dissolved. Cefazolin should be injected into a large muscle massIntravenous Administration: For direct injection reconstitution, dilute vials with approximately 10 ml Sterile Water for Injection for 500 mg and 1 gm. Inject the solution slowly over 3 to 5 minutes. For continuous infusion dilute reconstituted in 50 to 100 mL of one of the following solutions: 0.9% Sodium Chloride Injection,5% or 10% Dextrose Injection, 5% Dextrose and 0 .9% Sodium Chloride Injection.Pediatric Dosage: In pediatric patients, a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg of body weight for severe infections. Since safety of Cefazolin use in infants has not been established, it is not recommendedSide EffectsSwelling, redness, pain, or soreness at the injection site may occur. This medication may also rarely cause loss of appetite, nausea, vomiting, diarrhea or headachePrecautionsWhen Cefazolin is administered to patients with impaired renal function, a lower daily dosage is required or otherwise, seizures may occur. it should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.Use in Pregnancy & LactationThere are no adequate studies in pregnant women for this drug so this drug should be used during pregnancy only if clearly needed. Cefazolin is present in very low concentrations in the milk of nursing mothers so caution should be exercised.Drug InteractionProbenecid may decrease renal tubular secretion of Cefazolin, when used concurrently, resulting in increased Cefazolin blood levelsStorageDo not store above 30 0C. Keep away from light and out of the reach of children..
Tk.125.00/=
Celenta 200 Cap
Celenta 200 mg CapDescriptionCelenta is a non-steroidal anti-inflammatory agent (specific COX-2 inhibitor) having marked anti-inflammatory, analgesic and antipyretic activities with lower incidence of gastrointestinal adverse effects.IndicationsCelenta capsule is indicated for the relief of pain and inflammation of osteoarthritis and adult rheumatoid arthritis. Celenta is also indicated to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP); as an adjunct to usual care (e.g. endoscopic surveillance, surgery).Dosage & AdministrationFor osteoarthritis and rheumatoid arthritis, the lowest dose of Celenta should be sought for each patient. These doses can be given without regard to timing of meals.Osteoarthritis: For relief of the signs and symptoms of osteoarthritis the recommended oral dose is 200 mg per day as a single dose or as 100 mg twice daily. Rheumatoid arthritis: For relief of the signs and symptoms of rheumatoid arthiritis the recommended oral dose is 100-200 mg twice daily. Familial adenomatous polyposis: Usual medical care for FAP patients should be continued while on Celenta capsules. To reduce the number of adenomatous colorectal polyps in patients with FAP, the recommended oral dose is 400 mg twice daily to be taken with food. Hepatic insufficiency: The daily recommended dose of Celenta capsules in patients with moderate hepatic impairment should be reduced approximately by 50%.Side EffectsGastrointestinal side effects include abdominal pain, diarrhoea, dyspepsia, flatulence and nausea. Central nervous system side effects include dizziness, headache and insomnia. Other side effects include upper respiratory tract infection, skin rash, back pain and peripheral edema.PrecautionsCelecoxib cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids. Celecoxib should be prescribed with extreme caution in patients with a prior history of G.I. ulcer-disease or G.I. bleeding, hepatic and renal insufficiency, heart failure, those taking diuretics and ACE inhibitors, pre-existing asthma, elderly patients.Use in Pregnancy & LactationCelecoxib should be used during pregnancy only if the potential benefit justifies the potential risk to fetus. But in late pregnancy Celecoxib should be avoided because it may cause premature closure of ductus arteriosus. It is not known whether Celecoxib is excreted in human milk. Because many drugs are excreted in human milk and because of potential for serious adverse reactions in nursing infants from Celecoxib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.Over DosePatients should be managed by symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. No information is available regarding the removal of Celecoxib by hemodialysis but based on its high degree of plasma protein binding (>97%) dialysis is unlikely to be useful in overdose. Emesis and/or activated charcoal and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, hemodialysis or hemoperfusion may not be useful due to high protein binding...
Tk.8.00/=
Centradol 75 Tablet
DescriptionTapentadol is a centrally-acting synthetic analgesic. Although its exact mechanism of action is unknown, analgesic efficacy is thought to be due to µ opioid agonist activity and the inhibition of norepinephrine reuptake.IndicationsTapentadol is an opioid analgesic indicated for the management of moderate to severe acute pain in adults.Dosage & AdministrationIndividualize dosing according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient.Initiate Tapentadol at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours with or without food depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended.Side EffectsThe most common (≥10%) adverse reactions were nausea, vomiting, dizziness and somnolence.PrecautionsTapentadol should be administered with caution to patients with conditions accompanied by hypoxia, hypercapnia, respiratory problems such as: asthma, chronic obstructive pulmonary disease etc. Besides this, in case of patient with sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression should have to be cautious prior administration of Tapentadol. Patients receiving other µ-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with Tapentadol may exhibit additive CNS depression.Use in Pregnancy & LactationPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. This preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates whose mothers have been taking Tapentadol should be monitored for respiratory depression.Drug InteractionTapentadol is mainly metabolized by glucuronidation. The following substances have been included in a set of interaction studies without any clinically significant finding: Acetaminophen, Acetylsalicylic acid, Naproxen and Probenecid. The pharmacokinetics of Tapentadol were not affected when gastric pH or gastrointestinal motility were increased by Omeprazole and Metoclopramide, respectively.Over DoseAcute overdosage with opioids can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and sometimes pulmonary edema, bradycardia, hypotension and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.StorageStore in a cool and dry place. Keep away from light and moisture and out of reach of children...
Tk.17.00/=
Centradol ER Tablet
DescriptionTapentadol is a centrally-acting synthetic analgesic. Although its exact mechanism of action is unknown, analgesic efficacy is thought to be due to µ opioid agonist activity and the inhibition of norepinephrine reuptake.IndicationsTapentadol is an opioid analgesic indicated for the management of moderate to severe acute pain in adults.Dosage & AdministrationIndividualize dosing according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient.Initiate Tapentadol at a dose of 50 mg, 75 mg, or 100 mg every 4 to 6 hours with or without food depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability. Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are, therefore, not recommended.Side EffectsThe most common (≥10%) adverse reactions were nausea, vomiting, dizziness and somnolence.PrecautionsTapentadol should be administered with caution to patients with conditions accompanied by hypoxia, hypercapnia, respiratory problems such as: asthma, chronic obstructive pulmonary disease etc. Besides this, in case of patient with sleep apnea syndrome, myxedema, kyphoscoliosis, central nervous system (CNS) depression should have to be cautious prior administration of Tapentadol. Patients receiving other µ-opioid agonist analgesics, general anesthetics, phenothiazines, other tranquilizers, sedatives, hypnotics, or other CNS depressants (including alcohol) concomitantly with Tapentadol may exhibit additive CNS depression.Use in Pregnancy & LactationPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. This preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates whose mothers have been taking Tapentadol should be monitored for respiratory depression.Drug InteractionTapentadol is mainly metabolized by glucuronidation. The following substances have been included in a set of interaction studies without any clinically significant finding: Acetaminophen, Acetylsalicylic acid, Naproxen and Probenecid. The pharmacokinetics of Tapentadol were not affected when gastric pH or gastrointestinal motility were increased by Omeprazole and Metoclopramide, respectively.Over DoseAcute overdosage with opioids can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and sometimes pulmonary edema, bradycardia, hypotension and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.StorageStore in a cool and dry place. Keep away from light and moisture and out of reach of children...
Tk.20.00/=
Compiron syrup 50ml
DescriptionIron Polymaltose Complex is a polysaccharide-iron complex, which is a novel iron preparation used in the treatment of iron deficiency anaemia. Iron, an essential constituent of the body, is necessary for haemoglobin formation and for the oxidative process of living tissue. Compiron contains non-ionic ferric iron and polymaltose in a stable complex. This facilitates a controlled absorption of the ferric iron when it comes in contact with the mucosal cell surface. Being non-ionic, it does not release any free radicals and thus takes care of all the toxic effects found due to the release of free radicals by the traditional ionized iron salt preparations. It does not interact with the food components and other medications and so, unlike ferrous salts, there is no decrease in bioavailability of Iron Polymaltose Complex. This makes sure that with the consumption of this complex, iron gets utilized at a faster rate in the haemoglobin and myoglobin synthesis.Indications• Treatment of latent iron deficiency and iron deficiency anaemia including macrocytic anaemia,nutritional anaemia of infants, anaemia due to excessive haemorrhage and anaemia associated with infections and malignant disease.• Prevention and treatment of iron deficiency anaemia before, during and after pregnancy and during lactation.• For prophylactic therapy of iron deficiency to cover the recommended daily dietary allowances (RDA).Dosage & AdministrationDosage and duration of therapy are dependent upon the extent of iron deficiency and should be taken as directed by the physician.Adults: 10 ml once or twice dailyChildren (6 - 12 years): 10 ml dailyChildren (2 - 6 years): 5 ml dailyPremature infants & Infants: 3.33 mg of elemental iron/kg body weight (0.06 ml of Compiron drops/kg body weight) daily.Side EffectsThis preparation is well tolerated. However, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.PrecautionsN/AUse in Pregnancy & LactationRecommended.Over DoseIn case of overdosage, initially epigastric pain, diarrhoea and vomiting can occur and may include metabolic acidosis, convulsions and coma after apparent recovery. Should seek emergency medical attention in case of overdose. Initially an emetic should be given and then gastric lavage and general supportive measures should be employed...
Tk.30.00/=
Compiron syrup 100ml
DescriptionIron Polymaltose Complex is a polysaccharide-iron complex, which is a novel iron preparation used in the treatment of iron deficiency anaemia. Iron, an essential constituent of the body, is necessary for haemoglobin formation and for the oxidative process of living tissue. Compiron contains non-ionic ferric iron and polymaltose in a stable complex. This facilitates a controlled absorption of the ferric iron when it comes in contact with the mucosal cell surface. Being non-ionic, it does not release any free radicals and thus takes care of all the toxic effects found due to the release of free radicals by the traditional ionized iron salt preparations. It does not interact with the food components and other medications and so, unlike ferrous salts, there is no decrease in bioavailability of Iron Polymaltose Complex. This makes sure that with the consumption of this complex, iron gets utilized at a faster rate in the haemoglobin and myoglobin synthesis.Indications• Treatment of latent iron deficiency and iron deficiency anaemia including macrocytic anaemia,nutritional anaemia of infants, anaemia due to excessive haemorrhage and anaemia associated with infections and malignant disease.• Prevention and treatment of iron deficiency anaemia before, during and after pregnancy and during lactation.• For prophylactic therapy of iron deficiency to cover the recommended daily dietary allowances (RDA).Dosage & AdministrationDosage and duration of therapy are dependent upon the extent of iron deficiency and should be taken as directed by the physician.Adults: 10 ml once or twice dailyChildren (6 - 12 years): 10 ml dailyChildren (2 - 6 years): 5 ml dailyPremature infants & Infants: 3.33 mg of elemental iron/kg body weight (0.06 ml of Compiron drops/kg body weight) daily.Side EffectsThis preparation is well tolerated. However, a few side effects of oral iron preparations, including nausea, vomiting, constipation or diarrhoea may occur.PrecautionsN/AUse in Pregnancy & LactationRecommended.Over DoseIn case of overdosage, initially epigastric pain, diarrhoea and vomiting can occur and may include metabolic acidosis, convulsions and coma after apparent recovery. Should seek emergency medical attention in case of overdose. Initially an emetic should be given and then gastric lavage and general supportive measures should be employed...
Tk.50.00/=
Crisaderm Ointment
DescriptionCrisaderm contains 2% Crisaborole (w/w) in a petrolatum-based, white to off-white ointment and is for topical use. The active ingredient, Crisaborole, is a phosphodiesterase-4 (PDE-4) inhibitor, mainly acting on phosphodiesterase 4B (PDE4B), which causes inflammation. Chemically, Crisaborole is a phenoxybenzoxaborole. It contains a boron atom that helps penetrate the skin and is essential for its binding activity. Inhibition of PDE4B appears to suppress the release of tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines, proteins believed to be involved in the immune response and inflammation.IndicationsCrisaderm is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 3 months of age and older.Dosage & AdministrationApply a thin layer of Crisaderm twice daily to affected areas. Crisaderm is for topical use only and not for ophthalmic, oral, or intravaginal use.Side EffectsAllergic reactions- Crisaderm may cause allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness. The most common side effect of Crisaderm is application site pain, such as burning or stinging.PrecautionsHypersensitivity reactions, including contact urticaria have occurred in patients treated with Crisaderm. If signs and symptoms of hypersensitivity occur, discontinue Crisaderm immediately and initiate appropriate therapy.Use in Pregnancy & LactationRisk Summary: PregnancyThere is no available data with Crisaderm in pregnant women to inform the drug-associated risk for major birth defects and miscarriage. In animal reproduction studies, there were no adverse developmental effects observed with oral administration of crisaborole in pregnant rats and rabbits during organogenesis at doses up to 3 and 2 times, respectively, the maximum recommended human dose (MRHD).Risk Summary: LactationThere is no information available on the presence of Crisaderm in human milk. Crisaderm is systemically absorbed. The lack of clinical data during lactation precludes a clear determination of the risk of Crisaderm to a breastfed infant.Drug InteractionIn vitro studies using human liver microsomes indicated that under the conditions of clinical use, Crisaborole and metabolite 1 are not expected to inhibit cytochrome P450 (CYP) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4.In vitro human liver microsomes studies for metabolite 2 showed that it did not inhibit activities of CYP2C19, 2D6, and 3A4.StorageDo not store above 30 degree Celsius. Keep away from light and out of the reach of children...
Tk.500.00/=
Crizocent 250 Capsule 12's pack
DescriptionCrizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene’s expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.IndicationsCrizotinib is a kinase inhibitor indicated for the treatment of patients with-• Metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive• Metastatic NSCLC whose tumors are ROS1-positiveDosage & AdministrationRecommended Dose: 250 mg orally, twice daily• Renal Impairment: 250 mg orally, once daily in patients with severe renal impairment (creatinine clearance <30 mL/min) not requiring dialysis.Geriatric UseNo differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patientsHepatic ImpairmentCaution should be used in patients with hepatic impairmentRenal ImpairmentNo starting dose adjustment is needed for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.Increased exposure to crizotinib occurred in patients with severe renal impairment (CLcr <30 mL/min) not requiring dialysis. Crizotinib should be administered at a dose of 250 mg taken orally once daily in patients with severe renal impairment not requiring dialysis.Pediatric DoseThe safety and effectiveness of Crizotinib in pediatric patients have not been established.Side EffectsThe most common adverse reactions (≥25%) are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy.PrecautionsHepatotoxicity: Patients should undergo periodic liver testing. Crizotinib should be temporarily suspended, dose reduced or permanently suspended• Interstitial lung disease (ILD)/ Pneumonitis: Drug should be permanently discontinued in patients with ILD/ Pneumonitis• QT interval prolongation: Electrocardiograms and electrolytes in patients who have a history of or predisposition for QTc prolongation, or who are taking medications that prolong QT should be monitored. Crizotinib should be temporarily suspended, dose reduced or permanently suspended• Bradycardia: Crizotinib can cause bradycardia. Heart rate and blood pressure should be regularly monitored. Crizotinib should be temporarily suspended, dose reduced or permanently suspended• Severe visual loss: Ophthalmological evaluation should be performed. Crizotinib should be discontinued in severe visual loss• Embryo-fetal toxicity: Crizotinib can cause fetal harm. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraceptionUse in Pregnancy & LactationBased on its mechanism of action, Crizotinib can cause fetal harm when administered to a pregnant woman. There are no available data on the use of Crizotinib during pregnancy. Females of reproductive potential should be advised of the potential risk to a fetus and use of effective contraception.There is no information regarding the presence of Crizotinib in human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for adverse reactions in breastfed infants patients should not breastfeed during treatment with Crizotinib and for 45 days after the final dose.Geriatric UseNo differences in safety or efficacy were observed between older and younger patients. Clinical studies of Crizotinib in patients with ROS1-positive metastatic NSCLC did not include sufficient numbers of patients age 65 years and older to determine whether they respond differently from younger patientsHepatic ImpairmentCaution should be used in patients with hepatic impairmentRenal ImpairmentNo starting dose adjustment is needed for patients with mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment based on a population pharmacokinetic analysis.Increased exposure to crizotinib occurred in patients with severe renal impairment (CLcr <30 mL/min) not requiring dialysis. Crizotinib should be administered at a dose of 250 mg taken orally once daily in patients with ..
Tk.18,000.00/=
D-Rise 2000 IU Tablet
What is D-Rise® is and what it is used for?D-Rise® is the preparation of Cholecalciferol (Vitamin D3) 40,000 IU Capsule, 20,000 IU Capsule & 2000 IU Tablet. Cholecalciferol is a form of Vitamin D which is synthesized only when our skin gets exposed to the sunlight. For this reason, Cholecalciferol is referred as “sunshine vitamin”. This vitamin is very essential for healthy body functioning.is used for the prevention and treatment of Vitamin D deficiency symptoms including muscle weakness or muscle pain, joint pain, bone pain, mood swing, depression, dizziness and even osteomalacia or osteoporosis.Before you take D-Rise®?Do not take D-Rise and tell your doctor if you have one of the following casesHypersensitivity to vitamin D or any of the excipients in the productHypervitaminosis DNephrolithiasisDiseases or conditions resulting in hypercalcaemia and/or hypercalciuriaSevere renal impairmentTake special warnings and precautions if youhave impaired renal functionare receiving cardiac glycosidesare suffering from sarcoidosisHow to take D-Rise®?D-Rise capsule is taken whole orally with water, preferably after the meal.How much to take?AdultTreatment of vitamin D deficiency: 40000 IU/week for 7 weeks, followed by maintenance therapy (1400-2000 IU/day) for the next 3-4 months until target level of Vitamin D is achieved.Prevention of vitamin D deficiency: 20000 IU per monthChildren (12-18 Years)Treatment of vitamin D deficiency: 20000 IU, once every 2 weeks, up to 6 weeksPrevention of vitamin D deficiency: 20000 IU, once every 6 weeksPossible side effectsGenerally all nutritional supplements are considered to be safe and well tolerable. However, few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Cholecaciferol.How to store D-Rise® (Storage condition)Store in a cool dry place, protected from light...
Tk.2.50/=
Danlene Capsule
DescriptionDantrolene produce relaxation by affecting the contractile response of the skeletal muscle. In skeletal muscle, Dantrolene dissociates the excitation-contraction coupling, probably by interfering with the release of Ca++ from the sarcoplasmic reticulum.IndicationsIn Chronic Spasticity: Dantrolene is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Dantrolene is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders.A decision to continue the administration of Dantrolene on a long-term basis is justified if introduction of the drug into the patient's regimen:• produces a significant reduction in painful and/or disabling spasticity such as clonus, or• permits a significant reduction in the intensity and/or degree of nursing care required, or• rids the patient of any annoying manifestation of spasticity consideredimportant by the patient himself.In Malignant Hyperthermia: Oral Dantrolene is also indicated preoperatively to prevent or attenuate the development of signs of malignant hyperthermia in known, or strongly suspect, malignant hyperthermia susceptible patients who require anesthesia and/or surgery.Dosage & AdministrationFor Use in Chronic Spasticity: It is important that the dosage be titrated and individualized for maximum effect. The lowest dose compatible with optimal response is recommended.Each dosage level should be maintained for seven days to determine the patient’s response. If no further benefit is observed at the next higher dose, dosage should be decreased to the previous lower dose.Adults:25 mg once daily for seven days, then 25 mg t.i.d. for seven days, 50 mg t.i.d. for seven days, 100 mg t.i.d.Pediatric Patients:0.5 mg/kg once daily for seven days, then 0.5 mg/kg t.i.d. for seven days, 1 mg/kg t.i.d. for seven days, 2 mg/kg t.i.d.Therapy with a dose four times daily may be necessary for some individuals. Doses higher than 100 mg four times daily should not be used.For Malignant Hyperthermia:Preoperatively: 4 to 8 mg/kg/day of oral Dantrolene in 3 or 4 divided doses for one or two days prior to surgery, with the last dose being given approximately 3 to 4 hours before scheduled surgery with a minimum of water.Post Crisis Follow-up: Oral Dantrolene should also be administered following a malignant hyperthermia crisis, in doses of 4 to 8 mg/kg per day in four divided doses, for a one to three day period to prevent recurrence of the manifestations of malignant hyperthermia.Side EffectsThe most frequently occurring side effects of Dantrolene have been drowsiness, dizziness, weakness, general malaise, fatigue, and diarrhea.Other less frequent side effects are constipation, anorexia, abdominal cramps, nausea and/or vomiting, hepatitis, headache, visual disturbance, alteration of taste, insomnia, tachycardia, anemia, leukopenia, lymphocytic lymphoma, mental depression and mental confusion.PrecautionsDantrolene should be used with caution in patients with impaired pulmonary function, particularly those with obstructive pulmonary disease, and in patients with severely impaired cardiac function due to myocardial disease. Dantrolene is associated with pleural effusion with associated eosinophilia.Patients should be cautioned against driving a motor vehicle or participating in hazardous occupations while taking Dantrolene. Caution should be exercised in the concomitant administration of tranquilizing agents.Dantrolene might possibly evoke a photosensitivity reaction; patients should be cautioned about exposure to sunlight while taking it.Use in Pregnancy & LactationPregnancy: Pregnancy Category C.Nursing Mothers: Dantrolene should not be used in nursing mothers.Usage in Pediatric PatientsThe long-term safety of Dantrolene in pediatric patients under the age of 5 years has not been established.Drug InteractionDrowsiness may occur with Dantrolene therapy and the concomitant administration of CNS depressants such as sedatives and tranquilizing agents may result in further drowsiness.Hepatotoxicity has occurred more often in women over 35 years of age receiving concomitant estrogen therapy.Administration of Dantrolene may potentiate vecuronium-induced neuromuscular block...
Tk.10.00/=
Dapaglip 10 mg Tablet
Dapaglip 10 mg Tablet DescriptionDapagliflozin is an inhibitor of Sodium-Glucose Cotransporter 2 (SGLT2). By inhibiting SGLT2, Dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. Thus reduces blood sugar levels.IndicationsDapagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Dosage & AdministrationThe recommended starting dose of Dapagliflozin is 5 mg once daily, taken in the morning, with or without food. In patients tolerating Dapagliflozin 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. Assessment of renal function is recommended prior to initiation of Dapagliflozin therapy and periodically thereafter. Dapagliflozin should not be initiated in patients with an eGFR less than 60 mL/min/1.73 m2 . No dose adjustment is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m2 or greater). Dapagliflozin should be discontinued when eGFR is persistently less than 60 mL/min/1.73 m2.Side EffectsHypotension, impairment in renal function, hypoglycemia with concomitant use with insulin and insulin secretagogues, genital mycotic infections, increases in Low-Density Lipoprotein Cholesterol (LDL-C).PrecautionsHypotension: Before initiating Dapagliflozin, volume status should be assessed and correction on hypovolemia should be made in the elderly, in patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Impairment in renal function: Monitoring renal function is needed during therapy. Hypoglycemia: In patients taking insulin or an insulin secretagogue with Dapagliflozin, lower dose of insulin or the insulin secretagogue is considered to reduce the risk of hypoglycemia. Genital mycotic infections: Monitoring and treatment should be done if indicated. Increased LDL-C: Monitoring and treatment should be as per standard of care. Bladder Cancer: An imbalance in bladder cancers was observed in clinical trials. Dapagliflozin should not be used in patients with active bladder cancer and should be used with caution in patients with a prior history of bladder cancer.Use in Pregnancy & LactationPregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: Discontinue Dapagliflozin or discontinue nursing.Over DoseThere were no reports of overdose during the clinical development program for Dapagliflozin. The removal of Dapagliflozin by hemodialysis has not been studied.StorageDo not store above 300 C. Keep out of the reach of children...
Tk.30.00/=
Deflazit 24 Tablet
Deflazit 24 TabletDescriptionDeflazacort is an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity. Deflazacort is a glucocorticoid and 6mg of Deflazacort has approximately the same anti-in¬flammatory potency as 5mg Prednisolone or prednisone. Deflazacort works by acting within cells to prevent the release of certain chemicals that are important in the immune system. These chemicals are normally involved in producing immune and allergic responses, resulting in inflammation. Deflazacort also decreases the numbers of white blood cells circulating in the blood. This, along with the decrease in inflammatory chemicals, can prevent the rejection of organ transplants, as it prevents the body from attacking foreign tissue. It is useful for the treatment of certain types of leukaemia, where there is an abnormally large production of certain white blood cells, and for treating certain diseases that are caused by the immune system attacking tissues in the body (autoimmune diseases).Indications• Severe allergic reactions, e.g anaphylaxis• Asthma• Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica• Inflammatory bowel disease such as Crohn\'s disease and ulcerative colitis• Inflammatory disorders of the kidney, such as nephrotic syndrome and interstitial nephritis• Inflammatory eye disorders, eg uveitis, optic neuritis• Inflammatory skin disorders, including pemphigus vulgaris, bullous pemphigoid and pyoderma gangrenosum• Inflammatory disease of the skin and muscles (dermatomyositis)• Systemic lupus erythematosus• Mixed connective tissue disease• Rare condition involving inflammation in the walls of arteries (polyarteritis nodosa)• Sarcoidosis• Rheumatic carditis• Cancer of the bone marrow (multiple myeloma)• Acute and lymphatic leukaemia• Cancer of the lymph nodes (lymphoma)• Idiopathic thrombocytopenia purpura• Anaemia caused by the immune system attacking red blood cells (autoimmune haemolytic anaemia)• Helping to prevent the immune system attacking a transplanted organ, eg heart, liver, kidney etc.Dosage & AdministrationAdults: Usual maintenance 3-18 mg daily (acute disorders, initially up to 120 mg daily).Child 1 month–11 years: 0.25–1.5 mg/kg daily or on alternate days; up to 2.4 mg/kg (max.120 mg) daily in emergency situations.Child 12–17 years: 3–18 mg daily or on alternate days; up to 2.4 mg/kg (max. 120 mg) daily in emergency situations.When Deflazacort is used for long term, the maintenance dose should be kept as low as possible. Dosage may need to be increased during exacerbation of illness. It should not stop taking this medicine suddenly if it has been taking for more than three weeks. This is because long-term use of corticosteroids can suppress the natural production of corticosteroids by the adrenal glands, which means that the body becomes temporarily reliant on the medicine. When it is time to stop treatment the dose should be tapered down gradually, to allow the adrenal glands to start producing adequate amounts of natural steroids again.Hepatic Impairment: In patients with hepatic impairment, blood levels of Deflazacort may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.Side EffectsPsychological problems, weight gain, GI disturbances, musculoskeletal, endocrine, ophthalmic, fluid and electrolyte disturbance, susceptible to infection, impaired healing, hypersensitivity, bone fractures, osteoporosis, edema, peptic ulcer, Cushing\'s syndrome, skin atrophy, striae, menstrual disturbances, telangiectasia, acne, myocardial rupture following recent myocardial infarction, thromboembolism.PrecautionsThe following clinical conditions require special caution and frequent patient monitoring is necessary-Adrenal suppression and infection, child, adolescents, elderly, history of TB and steroid myopathy, hypertension, recent myocardial infarction, congestive heart failure, liver failure, renal impairment, diabetes mellitus and glaucoma (including family history), osteoporosis, corneal perforation, epilepsy, peptic ulcer, hypothyroidism, pregnancy and lactation.Use in Pregnancy & LactationPregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation.As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikely to ca..
Tk.30.00/=
Deflazit 50 ml Suspension
Deflazit 50 ml SuspensionDescriptionDeflazacort is an oxazoline derivative of prednisolone with anti-inflammatory and immunosuppressive activity. Deflazacort is a glucocorticoid and 6mg of Deflazacort has approximately the same anti-in¬flammatory potency as 5mg Prednisolone or prednisone. Deflazacort works by acting within cells to prevent the release of certain chemicals that are important in the immune system. These chemicals are normally involved in producing immune and allergic responses, resulting in inflammation. Deflazacort also decreases the numbers of white blood cells circulating in the blood. This, along with the decrease in inflammatory chemicals, can prevent the rejection of organ transplants, as it prevents the body from attacking foreign tissue. It is useful for the treatment of certain types of leukaemia, where there is an abnormally large production of certain white blood cells, and for treating certain diseases that are caused by the immune system attacking tissues in the body (autoimmune diseases).Indications• Severe allergic reactions, e.g anaphylaxis• Asthma• Rheumatoid arthritis, juvenile chronic arthritis, polymyalgia rheumatica• Inflammatory bowel disease such as Crohn\'s disease and ulcerative colitis• Inflammatory disorders of the kidney, such as nephrotic syndrome and interstitial nephritis• Inflammatory eye disorders, eg uveitis, optic neuritis• Inflammatory skin disorders, including pemphigus vulgaris, bullous pemphigoid and pyoderma gangrenosum• Inflammatory disease of the skin and muscles (dermatomyositis)• Systemic lupus erythematosus• Mixed connective tissue disease• Rare condition involving inflammation in the walls of arteries (polyarteritis nodosa)• Sarcoidosis• Rheumatic carditis• Cancer of the bone marrow (multiple myeloma)• Acute and lymphatic leukaemia• Cancer of the lymph nodes (lymphoma)• Idiopathic thrombocytopenia purpura• Anaemia caused by the immune system attacking red blood cells (autoimmune haemolytic anaemia)• Helping to prevent the immune system attacking a transplanted organ, eg heart, liver, kidney etc.Dosage & AdministrationAdults: Usual maintenance 3-18 mg daily (acute disorders, initially up to 120 mg daily).Child 1 month–11 years: 0.25–1.5 mg/kg daily or on alternate days; up to 2.4 mg/kg (max.120 mg) daily in emergency situations.Child 12–17 years: 3–18 mg daily or on alternate days; up to 2.4 mg/kg (max. 120 mg) daily in emergency situations.When Deflazacort is used for long term, the maintenance dose should be kept as low as possible. Dosage may need to be increased during exacerbation of illness. It should not stop taking this medicine suddenly if it has been taking for more than three weeks. This is because long-term use of corticosteroids can suppress the natural production of corticosteroids by the adrenal glands, which means that the body becomes temporarily reliant on the medicine. When it is time to stop treatment the dose should be tapered down gradually, to allow the adrenal glands to start producing adequate amounts of natural steroids again.Hepatic Impairment: In patients with hepatic impairment, blood levels of Deflazacort may be increased. Therefore the dose of Deflazacort should be carefully monitored and adjusted to the minimum effective dose.Renal Impairment: In renally impaired patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.Elderly: In elderly patients, no special precautions other than those usually adopted in patients receiving glucocorticoid therapy are necessary.Side EffectsPsychological problems, weight gain, GI disturbances, musculoskeletal, endocrine, ophthalmic, fluid and electrolyte disturbance, susceptible to infection, impaired healing, hypersensitivity, bone fractures, osteoporosis, edema, peptic ulcer, Cushing\'s syndrome, skin atrophy, striae, menstrual disturbances, telangiectasia, acne, myocardial rupture following recent myocardial infarction, thromboembolism.PrecautionsThe following clinical conditions require special caution and frequent patient monitoring is necessary-Adrenal suppression and infection, child, adolescents, elderly, history of TB and steroid myopathy, hypertension, recent myocardial infarction, congestive heart failure, liver failure, renal impairment, diabetes mellitus and glaucoma (including family history), osteoporosis, corneal perforation, epilepsy, peptic ulcer, hypothyroidism, pregnancy and lactation.Use in Pregnancy & LactationPregnancy: Deflazacort does cross the placenta. However, when administered for prolonged periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation.As with all drugs, corticosteroids should only be prescribed when the benefits to the mother and child outweigh the risks.Nursing Mother: Corticosteroids are excreted in breast milk, although no data are available for Deflazacort. Doses of up to 50 mg daily of Deflazacort are unlikel..
Tk.175.00/=
Denosis 120 Injection
Denosis 120 InjectionDescriptionDenosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.IndicationsDenosumab is a RANK ligand (RANKL) inhibitor indicated for:- Prevention of skeletal-related events in patients with bone metastases from solid tumors- Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity- Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapyDosage & AdministrationDenosumab is intended for subcutaneous route only and should not be administered intravenously, intramuscularly, or intradermally.Bone Metastasis from Solid Tumors : The recommended dose of Denosumab is 120 mg administered as a subcutaneous injection every 4 weeks in the upper arm, upper thigh, or abdomen. Calcium and vitamin D should be administered as necessary to treat or prevent hypocalcemia.Limitations of useIt is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.Giant Cell Tumor of Bone: The recommended dose of Denosumab is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. It should be administered subcutaneously in the upper arm, upper thigh, or abdomen. Calcium and vitamin D should be administered as necessary to treat or prevent hypocalcemia.Hypercalcemia of Malignancy : The recommended dose of Denosumab is 120 mg administered every 4 weeks with additional 120 mg doses on Days 8 and 15 of the first month of therapy. It should be administered subcutaneously in the upper arm, upper thigh, or abdomen.Side EffectsBone Metastasis from Solid Tumors: Most common adverse reactions (per-patient incidence greater than or equal to 25%) were fatigue/asthenia, hypophosphatemia, and nausea- Giant Cell Tumor of Bone: Most common adverse reactions (per-patient incidence greater than or equal to 10%) were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity- Hypercalcemia of Malignancy: Adverse reactions in greater than 20% of patients were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrheaPrecautionsSame Active Ingredient: Patients receiving Denosumab 120 mg should not receive Denosumab 60 mg- Hypersensitivity including anaphylactic reactions may occur. If an anaphylactic or other clinically significant allergic reaction occurs, appropriate therapy should be initiated and Denosumab therapy permanently discontinued- Hypocalcemia: Must be corrected before initiating Denosumab. May worsen, especially in patients with renal impairment. Patients should be adequately supplemented with calcium and vitamin D- Osteonecrosis of the jaw: Has been reported with Denosumab. Patients should be monitored for symptoms. An oral examination should be performed and symptoms should be monitored.- Invasive dental procedure should be avoided during treatment with Denosumab- Atypical femoral fractures: Have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture- Embryo-Fetal Toxicity: Denosumab can cause fetal harm when administered to a pregnant womanUse in Pregnancy & LactationPregnancy Category D. Denosumab can cause fetal harm when administered to a pregnant woman. Women should be advised not to become pregnant when taking Denosumab.Lactation:It is not known whether Denosumab is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Denosumab, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric Use:The safety and efficacy of Denosumab have not been established in pediatric patients except in skeletally mature adolescents with giant cell tumor of bone. Denosumab is recommended only for treatment of skeletally mature adolescents with giant cell tumor of bone.Geriatric Use:No overall differences in safety or efficacy were observed between these patients and younger patients.Renal Impairment:Greater risk of developing hypocalcemia was observed with increasing renal impairment, and with inadequate/no calcium supplementation.Use in females:Patients are advised to contact their healthcare provider if they become pregnant, or a pr..
Tk.35,000.00/=
Denosis 60 Injection
Denosis 60 InjectionDescriptionDenosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.IndicationsDenosumab is a RANK ligand (RANKL) inhibitor indicated for:Treatment of postmenopausal women with osteoporosis at high risk for fracture- Treatment to increase bone mass in men with osteoporosis at high risk for fracture- Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer- Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancerDosage & AdministrationThe recommended dose of Denosumab is 60 mg administered as a single subcutaneous injection once every 6 months. It should be administered via subcutaneous injection in the upper arm, the upper thigh, or the abdomen. All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily.Renal Impairment:No dose adjustment is necessary for patients with renal impairment. Patients with creatinine clearance < 30 mL/min or receiving dialysis are at risk for hypocalcemia.Hepatic Impairment:No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of DenosumabSide EffectsPostmenopausal osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trialsMale Osteoporosis: Most common adverse reactions (> 5% and more common than placebo) were: back pain, arthralgia, and nasopharyngitisBone loss due to hormone ablation for cancer: Most common adverse reactions (≥ 10% and more common than placebo) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trialsPrecautionsSame Active Ingredient: Patients receiving Denosumab 60 mg should not receive Denosumab 120 mgHypersensitivity including anaphylactic reactions may occur. Treatment should be discontinued permanently if a clinically significant reaction occurs.Hypocalcemia: Must be corrected before initiating Denosumab. May worsen, especially in patients with renal impairment. Patients should be adequately supplemented with calcium and vitamin D.Osteonecrosis of the jaw: Has been reported with Denosumab. Patients should be monitored for symptoms.Atypical femoral fractures: Have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture.Serious infections including skin infections: May occur, including those leading to hospitalization. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of infection, including cellulitis.Dermatologic reactions: Dermatitis, rashes, and eczema have been reported. Discontinuing Denosumab should be considered if severe symptoms develop.Severe Bone, Joint, Muscle Pain may occur. Use should be discontinued if severe symptoms develop.Suppression of bone turnover: Significant suppression has been demonstrated. The patient should be monitored for the consequences of bone over suppression.Use in Pregnancy & LactationPregnancy Category XDenosumab is contraindicated in women who are pregnant. It may cause fetal harm when administered to a pregnant woman.Lactation:It is not known whether Denosumab is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Denosumab, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Pediatric UseDenosumab is not recommended in pediatric patients. Safety and effectiveness of Denosumab have not been established in pediatric patients.Use in MalesDenosumab may cause fetal harm. The extent to which Denosumab is present in seminal fluid is unknown. There is a potential for fetal exposure to Denosumab when a man treated with it has unprotected sexual intercourse with a pregnant partner. The risk of fetal harm is likely to be low. Men being treated with Denosumab who have a pregnant partner should be advised of this potential risk.Drug InteractionIn subjects with postmenopausal osteoporosis, Denosumab (60 mg subcutaneous injection) did not affect the pharmacokinetics of Midazolam, which is metabolize..
Tk.18,000.00/=
Dermomix 15 gm Cream
Dermomix CreamDescriptionDermomixTM Cream is a multiple combination cream which exhibits anti-bacterial, anti-protozoal, anti-fungal and steroid properties to control inflammation. Ofloxacin is a broad-spectrum antibiotic that acts against many gram-positive and gram-negative bacteria. Ornidazole belongsto the nitroimidazole group of antibiotics and is used to treat amoeba and trichomonas infections. Terbinafine is a topical antifungal and antiparasitic drug. Clobetasol is a potent corticosteroid which exhibits anti-inflammatory, anti-pruritic and vasoconstrictive properties.IndicationsDermomixTM Cream is indicated in the treatment of eczema, dermatitis, tinea infections, bacterial infections and scalp psoriasis.Dosage & AdministrationApply to the affected area and rub evenly onto the skin twice dailySide EffectsBurning, itching, irritation, dry skin eczema.PrecautionsDo not swallow. For external use only.Use in Pregnancy & LactationThe safe use of this preparation during pregnancy & lactation has not been established.Drug InteractionNo hazardous interactions have been reportedOver DoseAcute overdosage is very unlikely to occur. However, in the case of chronic overdose or misuse the features of hypercortisolism may appear.StorageDo not store above 30 0 C. Keep away from light and out of the reach of children. Do not freeze..
Tk.150.00/=